There is paucity of data comparing drug eluting stent (DES) with bare metal stent (BMS) in patients with symptomatic femoropopliteal peripheral artery disease (PAD). The polymer-free Zilver PTX and polymer-based ELUVIA are the most used DES for management of femoropopliteal lesions, and both are paclitaxel eluting. Zilver PTX trial was the first randomized trial comparing DES with BMS in the setting of secondary randomization in patients with acute percutaneous transluminal angioplasty (PTA) failure [ ]. This study found significant improvement in clinical benefits and freedom from target lesion revascularization (TLR) in provisional DES group compared with provisional BMS group at 5 years follow-up. Primary randomization in this study compared DES with PTA. BATTLE trial published in 2020 compared polymer-free DES with BMS [ ]. This study failed to show superiority of DES at 2 years. Recently published EMINENT trial compared polymer-based DES with contemporary BMS. It found significant improvement in primary patency rates in DES group at 1 year follow up [ ]. We performed this meta-analysis to gather more evidence regarding safety and efficacy of DES compared with BMS in symptomatic patients with femoropopliteal lesions.